ストックスクリーナーアプリを入手
43.40
7.28%
-3.41
アフターアワーズ：
43.40
前日終値:
$46.81
開ける：
$47.08
24時間の取引高:
3.35M
Relative Volume:
2.35
時価総額：
$5.29B
収益：
$47.30M
当期純損益:
$-408.73M
株価収益率:
-12.10
EPS:
-3.5865
ネットキャッシュフロー:
$-303.86M
1週間 パフォーマンス:
-11.66%
1か月 パフォーマンス:
-21.56%
6か月 パフォーマンス:
-13.22%
1年 パフォーマンス:
+15.83%
1日の値動き範囲:
$42.47
$47.19
1週間の範囲:
$42.47
$49.60
52週間の値動き範囲:
$27.07
$61.76
Scholar Rock Holding Corp Stock (SRRK) Company Profile
名前
Scholar Rock Holding Corp
セクター
電話
857-259-3860
住所
301 BINNEY STREET, CAMBRIDGE, MA
Compare SRRK vs VRTX, MRNA, REGN, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SRRK
Scholar Rock Holding Corp
|
43.40 | 5.92B | 47.30M | -408.73M | -303.86M | -3.5865 |
VRTX
Vertex Pharmaceuticals Inc
|
503.50 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
203.21 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
726.47 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
912.87 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
207.68 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-21 | 開始されました | Canaccord Genuity | Buy |
| 2026-01-09 | 開始されました | Citigroup | Buy |
| 2025-11-18 | 開始されました | Wolfe Research | Outperform |
| 2025-10-09 | 開始されました | BofA Securities | Buy |
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-09-15 | 開始されました | Leerink Partners | Outperform |
| 2025-08-21 | 再開されました | Jefferies | Buy |
| 2025-07-30 | 再開されました | Raymond James | Strong Buy |
| 2025-07-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-11-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-10-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-03-28 | 開始されました | Raymond James | Strong Buy |
| 2023-10-25 | アップグレード | Jefferies | Hold → Buy |
| 2023-04-03 | 再開されました | Piper Sandler | Overweight |
| 2022-09-19 | 再開されました | H.C. Wainwright | Buy |
| 2022-07-12 | 開始されました | Truist | Buy |
| 2022-03-23 | 開始されました | H.C. Wainwright | Buy |
| 2021-12-22 | ダウングレード | Jefferies | Buy → Hold |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-01-11 | 開始されました | Credit Suisse | Outperform |
| 2021-01-06 | 開始されました | JP Morgan | Overweight |
| 2020-03-12 | 開始されました | Robert W. Baird | Outperform |
すべてを表示
Scholar Rock Holding Corp (SRRK) 最新ニュース
Investigation launched into Scholar Rock's offi... - Pluang
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm - TradingView
Scholar Rock Holding Corp. Cash Flow – HAN:2QK - TradingView
Net income of Scholar Rock Holding Corp. – HAN:2QK - TradingView
EBIT of Scholar Rock Holding Corp. – HAN:2QK - TradingView
SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing - Stocktwits
Form 4 Scholar Rock Holding Corp For: 26 September By Investing.com - Investing.com Canada
No common shares appear in Scholar Rock (SRRK) COO Keith Woods’s reported position after a gift to a trust. - Stock Titan
Scholar Rock Holding Corp (SRRK) Gains Wedbush Spotlight Amid Valuation and Insider Activity Insights - GuruFocus
Scholar Rock added to Wedbush's Best Ideas List - Seeking Alpha
Piper Sandler reiterates Scholar Rock stock rating on uptake view By Investing.com - Investing.com Australia
Wedbush Rates Scholar Rock (SRRK) Outperform Amid Attractive Pri - GuruFocus
Piper Sandler reiterates Scholar Rock stock rating on uptake view - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
SRRK Maintains Buy Rating by Truist Securities -- Price Target R - GuruFocus
Truist raises Scholar Rock stock price target on drug pricing update By Investing.com - Investing.com Australia
Truist raises Scholar Rock stock price target on drug pricing update - Investing.com
Truist Lifts Price Target on Scholar Rock Holding to $77 From $76, Keeps Buy Rating - Yahoo Finance
Scholar Rock (SRRK) Short Interest & Short Float | Updated Sep 2026 $SRRK - MarketBeat
No payment changed hands when Scholar Rock (SRRK) CEO David Hallal transferred 36,652 shares to a family trust. - Stock Titan
Scholar Rock’s Isembyld approval sets up rapid sales ramp - S&P Global
Scholar Rock Holding Corporation (SRRK) stock price, news, quote and history - Yahoo Finance UK
Scholar Rock Holding Corporation (SRRK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Scholar Rock (NASDAQ:SRRK) Shares Up 6% Following Analyst Upgrade - MarketBeat
Weight-loss drug developers line up to tap lucrative market as competition heats up - reuters.com
THNR's Weight-Loss Index Swaps Hims & Hers for Gilead - ETF Database
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
SRRK Maintains Overweight Rating by JP Morgan -- Price Target Ra - GuruFocus
Scholar Rock (NASDAQ:SRRK) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
JPMorgan raises Scholar Rock stock price target to $70 on launch outlook - Investing.com Nigeria
Bank of America Corp DE Takes $53.47 Million Position in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding (SRRK) Won FDA Approval, Is The Stock Still Trading At A Discount? - Simply Wall Street
Scholar Rock (NASDAQ:SRRK) Raised to Strong-Buy at Jefferies Financial Group - MarketBeat
HC Wainwright Lowers Earnings Estimates for Scholar Rock - MarketBeat
Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale? - Insider Monkey
Scholar Rock (NASDAQ: SRRK) Updates FDA Safety Requirements for ISEMBYLD Post-Approval - Kalkine Media
Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst Revisions - Yahoo Finance
Piper Sandler raises Scholar Rock stock price target on pricing By Investing.com - Investing.com South Africa
Scholar Rock (SRRK) Gains FDA Approval for Isembyld Amid Post-Ma - GuruFocus
Scholar Rock Shares Fall After Barclays Downgrade - marketscreener.com
Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says - marketscreener.com
Scholar Rock (SRRK) Shares Drop Amid Barclays Downgrade Despite FDA Approval - GuruFocus
Scholar Rock clarifies post-marketing requirements for ISEMBYLD after FDA approval - Investing.com
Scholar Rock (NASDAQ:SRRK) Shares Down 7.1%Here's What Happened - MarketBeat
Form 8K Scholar Rock Holding Corp For: 15 September By Investing.com - Investing.com Australia
SRRK Maintained by Wedbush -- Price Target Raised to $70 - GuruFocus
UBS reiterates Buy on Scholar Rock stock, keeps $60 price target - Investing.com
Scholar Rock Updates FDA Post-Marketing Safety Requirements for ISEMBYLD Following Investor Call Correction - kalkinemedia.com
H.C. Wainwright raises Scholar Rock stock price target on FDA approval - Investing.com UK
SRRK Maintained by HC Wainwright & Co. -- Price Target Raised to $70 - GuruFocus
Barclays downgrades Scholar Rock stock rating on valuation By Investing.com - Investing.com Australia
Scholar Rock Holding Corp (SRRK) 財務データ
収益
当期純利益
現金流量
EPS
Scholar Rock Holding Corp (SRRK) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| FLIER JEFFREY S. | Director |
Jul 01 '26 |
Sale |
53.88 |
3,053 |
164,490 |
27,856 |
| Gilman Michael | Director |
Jul 01 '26 |
Sale |
53.87 |
2,544 |
137,058 |
59,511 |
| Burow Kristina | Director |
Jul 01 '26 |
Sale |
53.74 |
3,053 |
164,064 |
114,657 |
| Reed Joshua | Director |
Jul 01 '26 |
Sale |
53.74 |
3,053 |
164,067 |
19,518 |
| Peng Katie | Director |
Jul 01 '26 |
Sale |
53.88 |
5,446 |
293,405 |
34,301 |
0.76%
0.87%
大文字化:
|
ボリューム (24 時間):